FY2021 EPS Estimates for Fate Therapeutics, Inc. (NASDAQ:FATE) Decreased by Cantor Fitzgerald Fate Therapeutics, Inc. (NASDAQ:FATE) – Stock analysts at Cantor Fitzgerald dropped their FY2021 earnings estimates for shares of Fate Therapeutics in a note issued to investors on Thursday, February 25th. Cantor Fitzgerald analyst A. Young now anticipates that the biopharmaceutical company will post […]

Liposomal Doxorubicin Volume Analysis, Segments, Value Share and Key Trends 2021-2030 Growth Prospects of the Global Liposomal Doxorubicin Market The comprehensive study on the Liposomal Doxorubicin market provides crucial insights to the stakeholders who are vying to solidify their presence in the current and future market landscape. The various factors that are likely to shape […]

Q2 2021 EPS Estimates for Genmab A/S (NASDAQ:GMAB) Decreased by Truist Securiti Genmab A/S (NASDAQ:GMAB) – Stock analysts at Truist Securiti dropped their Q2 2021 earnings per share (EPS) estimates for Genmab A/S in a note issued to investors on Thursday, February 25th. Truist Securiti analyst A. Goonewardene now forecasts that the company will post […]

Car T Cell Therapy Market Volume Analysis, Size, Share and Key Trends 2020-2028 “Car T Cell Therapy Market report with COVID 19 impact on Industry contains key global Car T Cell Therapy companies to define, describe and analyze the sales volume, value, and market share. It focuses on the global Car T Cell Therapy status, […]

Weizmann study identifies genes connected to myeloma drug resistance Researchers from the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center have found 30 genes that seem to be responsible for the resistance that multiple myeloma shows to treatment, which may help lead to more informed, personalized treatment for patients. Malignant myeloma is […]

Multiple Myeloma: MRD Detection, Single Cell RNA Sequencing, and Cell Free DNA Earn CME: https://www.naccme.com/program/19-lm-05 In this webcast from the ‘Multiple Myeloma: Treatment Challenges and Updates’ symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Raphael Fonseca discusses whether recent advances translate to treatment selection. © 2019 Imedex, an HMP Company